Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas

Cancer Chemotherapy and Pharmacology
S TomaR Rosso

Abstract

We undertook this phase II study to evaluate the efficacy and toxicity of epidoxorubicin and ifosfamide in the treatment of locally advanced and/or metastatic soft-tissue sarcomas. We used escalating doses of epidoxorubicin (from 60 to 75 mg/m2) on day 1 and 1.2 g/m2 ifosfamide on days 1-5. Chemotherapy courses were repeated every 3-4 weeks. A total of 16 patients--13 who had not previously been treated and 3 who had undergone prior therapy with anthracyclines--entered the study. In all, 15 patients were evaluable for response and 16, for toxicity. At least two courses of chemotherapy were given. A complete remission (CR) was seen in 1 patient, a partial remission (PR) in 5, and a minor response (MR) in 1, for an objective response rate (CR + PR) of 40% (6/15); this value reached 50% in non-pretreated patients (6/12). Stable disease (SD) was observed in 40% (6/15) of patients. The relative dose intensity of epidoxorubicin ranged from 10 to 23.3 mg/m2 (median, 16.6 mg/m2). The time to objective response ranged from 4 to 12 weeks (median, 8.5 weeks). The duration of response was 4 months for the single CR, and that for the five PRs was 6+ months (range, 4-18 months). Toxicity was evaluated according to WHO criteria in 16 patients...Continue Reading

References

Jun 1, 1977·Cancer Treatment Reviews·H M Pinedo, Y Kenis
Jan 1, 1977·Oncology·E T CreaganH F Bisel
Jul 1, 1986·European Journal of Cancer & Clinical Oncology·C A MeanwellG Blackledge
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·E WiltshawC Fisher
Jan 1, 1988·Cancer Chemotherapy and Pharmacology·B M CantwellA L Harris
Sep 1, 1988·European Journal of Cancer & Clinical Oncology·J L MansiR Stuart-Harris
Mar 1, 1987·European Journal of Cancer & Clinical Oncology·V H BramwellR Sylvester
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·P DombernowskyG Blackledge
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·J H HartlappJ C Jensen
Aug 1, 1983·European Journal of Cancer & Clinical Oncology·V H BramwellD Markham
Jan 1, 1982·European Journal of Cancer & Clinical Oncology·C P KarakousisH C Park
Jan 1, 1981·Cancer·A B MillerA Winkler

❮ Previous
Next ❯

Citations

Jan 1, 1992·Cancer Chemotherapy and Pharmacology·D BartkowiakE Röttinger
Jan 1, 1991·Journal of Cancer Research and Clinical Oncology·W P BradeC E Araujo
Jul 10, 2009·Cancer Chemotherapy and Pharmacology·Romain CoriatFrançois Goldwasser
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A V BoddyJ R Idle
Apr 22, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R PalumboS Toma
Jan 1, 1993·Cancer Investigation·B ChevallierM L Vo Van

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.